- Home
- DXCM vs ARGX Comparison
DXCM vs ARGX Comparison
Compare DXCM & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- ARGX
- Stock Information
- Founded
- DXCM 1999
- ARGX 2008
- Country
- DXCM United States
- ARGX Netherlands
- Employees
- DXCM N/A
- ARGX N/A
- Industry
- DXCM Medical/Dental Instruments
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXCM Health Care
- ARGX Health Care
- Exchange
- DXCM Nasdaq
- ARGX Nasdaq
- Market Cap
- DXCM 35.7B
- ARGX 40.4B
- IPO Year
- DXCM 2005
- ARGX 2017
- Fundamental
- Price
- DXCM $68.29
- ARGX $591.87
- Analyst Decision
- DXCM Strong Buy
- ARGX Strong Buy
- Analyst Count
- DXCM 17
- ARGX 20
- Target Price
- DXCM $99.82
- ARGX $682.00
- AVG Volume (30 Days)
- DXCM 4.4M
- ARGX 314.1K
- Earning Date
- DXCM 04-24-2025
- ARGX 05-08-2025
- Dividend Yield
- DXCM N/A
- ARGX N/A
- EPS Growth
- DXCM 9.35
- ARGX N/A
- EPS
- DXCM 1.42
- ARGX 12.78
- Revenue
- DXCM $4,033,000,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- DXCM $16.49
- ARGX $57.86
- Revenue Next Year
- DXCM $15.58
- ARGX $31.90
- P/E Ratio
- DXCM $47.96
- ARGX $43.78
- Revenue Growth
- DXCM 11.34
- ARGX 77.22
- 52 Week Low
- DXCM $62.34
- ARGX $352.77
- 52 Week High
- DXCM $141.99
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- DXCM 33.19
- ARGX 42.34
- Support Level
- DXCM $69.92
- ARGX $582.07
- Resistance Level
- DXCM $76.01
- ARGX $598.06
- Average True Range (ATR)
- DXCM 2.45
- ARGX 13.05
- MACD
- DXCM -0.17
- ARGX -0.35
- Stochastic Oscillator
- DXCM 20.36
- ARGX 33.69
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.